Document is current
Any future updates will be listed below
-
Authors
Yu, Tengteng
Chaganty, Bharat https://orcid.org/0000-0003-3281-6218
Lin, Liang
Xing, Lijie
Ramakrishnan, Boopathy
Wen, Kenneth
Hsieh, Phillip A.
Wollacott, Andrew
Viswanathan, Karthik
Adari, Hedy
Cho, Shih-Feng
Li, Yuyin
Chen, Hailin
Yang, Wenjuan
Xu, Yan https://orcid.org/0000-0002-6167-3319
An, Gang
Qiu, Lugui
Munshi, Nikhil
Babcock, Gregory
Shriver, Zachary
Myette, James R.
Anderson, Kenneth C. https://orcid.org/0000-0002-6418-0886
Tai, Yu-Tzu https://orcid.org/0000-0001-6199-3569
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA100707, P01CA155258, P50 CA100707, P01CA155258)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 3 August 2020
Revised: 16 September 2020
Accepted: 2 October 2020
First Online: 2 November 2020
Conflict of interest
: B.C., B.R., A.W., K.V., H.A, G.B., Z.S., and J.R.M. are employees of Visterra Inc. N.M. serves on advisory boards to Millennium-Takeda, Celgene, and Novartis. K.C.A. serves on advisory boards Celgene, Millennium-Takeda, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Sanofi-Aventis and is a Scientific founder of OncoPep and C4 Therapeutics. All other authors declare no potential conflicts of interest.
